Seedsupply

SEEDSUPPLY INC. is a Japanese biotechnology company specializing in early-stage drug discovery through its proprietary Binder Selection Technology (BST). Spun out from Takeda Pharmaceutical Company in 2017, the company focuses on identifying hit compounds for challenging drug targets, particularly membrane proteins like GPCRs, transporters, and ion channels. SEEDSUPPLY offers both discovery screening services to global pharmaceutical partners and maintains an internal pipeline of small molecule programs. Its platform leverages an improved Affinity Selection Mass Spectrometry (ASMS) approach to enable native-state binding assays without the need for target solubilization. The company is headquartered in the Shonan Health Innovation Park in Fujisawa, Japan.